At Regeneron, we move science to medicine, because our world is

MEANT FOR **MORE**

PharmD

PROGRAM

2026 - 2028

REGENERON®

CONTENTS

> **At the heart of The Regeneron Way is our shared passion for scientific excellence, collaborative innovation, and transformative patient care.**

Allison Nguyen, PharmD
GRADUATE OF RUTGERS UNIVERSITY

ABOUT REGENERON

Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.

At Regeneron we make it our business every day to bring innovative thinking to the challenge of discovering and developing new medicines. Our pursuit has one singular intent – to improve therapeutic outcomes for patients.

THE REGENERON WAY

LEAD WITH SCIENCE

Science drives our business and passion drives our science. Whether you're doing science, supporting science or delivering science. It's what we do.

TAKE ON BIG IDEAS

We take the long view and tackle the big ideas, the unsolvable problems, and the bottlenecks that get in the way. We pursue ideas with passion and courage, to make a real difference.

MAKE IT HAPPEN

It may not always be easy, but we figure it out and get it done. We have little appetite for unnecessary bureaucracy that can get in the way of innovation or quality.

BE GREAT TOGETHER

While others talk about teamwork, we actually do it. When you work with smart, fun people, you bring out the best in each other and can do the extraordinary.

DO WHAT'S RIGHT

We do well by doing good. We act with integrity and pride ourselves on doing the right thing - by each other, our communities, our patients and the world around us.

THE PHARMD PROGRAM

The PharmD Program is an intensive, rotational, interdisciplinary program for PharmD professionals.

The objective for the the PharmD Program is to provide training by Regeneron subject matter experts and hands-on experience in a variety of Global Development roles.

The PharmD Program is for highly motivated individuals seeking to build a career in the biopharmaceutical industry with a foundation in Development Operations & Portfolio Management, Clinical Sciences, Regulatory Strategy, Regulatory Labeling and Advertising & Promotion, and/or Safety Sciences.



OBJECTIVES

PharmD Associates will:

Gain knowledge of biopharmaceutical processes in a variety of Global Development roles

Develop a balanced foundation of skills through **hands-on industry experience in functional areas,** including clinical development, regulatory affairs, and patient safety

Cultivate technical and non-technical skills through diverse **cross-functional experiences, ongoing mentorship, and targeted training**

Engage in **interdisciplinary professional development sessions** to maximize the learning and overall experience at Regeneron

WHO IS THE IDEAL PHARMD PROGRAM CANDIDATE?

The ideal applicant is **intellectually curious, hard-working, and passionate** about science and continuous learning.

Qualified candidates are graduates of an accredited pharmacy program. These individuals have a high academic standing preferably with some relevant experience. They have strong analytical, communication, and organizational skills and are adept at leadership and team roles.

Throughout the program, participants will cultivate technical and non-technical skills through diverse cross-functional experiences, ongoing mentorship, and targeted training.

Each assignment in this **2-year development program** will expose participants to critical issues and decision-making processes to gain broad experience across several clinical/ scientific research areas.

The selected program participants will acquire high level knowledge of the business and department operations, as well as gain track-specific work experience.

PROGRAM STRUCTURE OVERVIEW

24-months in one of these functional areas:

FUNCTIONAL AREAS

TRACK 1
DEVELOPMENT OPERATIONS & PORTFOLIO MANAGEMENT

In DO & PM, the Associate will focus on Clinical Trial Management and Program Management supporting and owning key activities across clinical trials and strategic programs in the Development Portfolio.

Current First Year PharmD Associate

SOPHIA SCHULTE, PHARMD

Graduate of the Medical College of Wisconsin

Currently working in Clinical Trial Management supporting the Internal Medicine portfolio.

"The PharmD program offers a unique environment that challenges you, supports you, and prepares you for a successful career within the biopharmaceutical industry. This rotational based program offers an incredible opportunity to see both the scientific and operational sides of drug development. During my time, I've been given the chance to work on projects that truly impact patients, while learning from experts who are passionate about what they do. "

Current Second Year PharmD Associate

DOUGLAS LEMENZE, PHARMD

Graduate of Rutgers University

Currently working in DPM supporting the Internal Medicine portfolio.

"Regeneron is a company that leads with science and discovery to improve the lives of patients on a global level. Likewise, the passion and commitment to implementing these therapies is seen across all of the employees. The PharmD Program allows the Associates to gain valuable experience and opportunities across multiple functional areas, fostering growth and expertise. It is an amazing place to lay the foundation for a career within the biopharmaceutical industry. "

In Clinical Trial Management, the Associate will:

- Perform key activities during the clinical trial start-up, maintenance, and close-out phases
- Contribute to program/study strategic feasibility and country and site selection
- Conduct site initiation visits (including presentations), site monitoring visits, and oversee patient enrollment planning
- Review clinical study budgets and timelines, and interact cross-functionally with various internal team members and external clinical sites and vendors

In Program Management, the Associate will:

- Integrate drug development planning and execution from early development through BLA submission
- Develop and manage budgets, timelines, and project plans
- Participate in and facilitate governance meetings, including the Global Clinical Sub-Team, Strategic Program Team, Development Program Reviews, and Protocol Review Committee
- Conduct scenario planning and risk mitigation

FUNCTIONAL AREAS

TRACK 2
CLINICAL SCIENCES

In Clinical Sciences, the Associate will participate in activities throughout the lifetime of a drug development program from supporting the development of pre-IND/IND documents through regulatory submissions. The Clinical Scientist Associate will play an instrumental role through all phases of clinical development to bring life-changing medicines to patients. Studies supported may include translational research, clinical experimental sciences, early/late phase clinical trials, and post-marketing requirements.

Current First Year PharmD Associate

JANE WITKIN, PHARMD

Graduate of Rutgers University

Currently working in Clinical Sciences supporting studies in the Genetic Medicines portfolio.

"Joining Regeneron as a Clinical Science Associate, I was quickly integrated into the Genetic Medicines development unit, allowing me to contribute meaningfully to ongoing studies from the start. The program's rotational structure, paired with exceptional mentorship from dedicated leaders and access to a robust pipeline, provides an unparalleled foundation for building a successful career in the biopharmaceutical industry."

Current Second Year PharmD Associate

SLADE SCHNEIDER, PHARMD

Graduate of the University of California, San Francisco

Currently working in Clinical Sciences supporting studies in the Internal Medicine and Genetic Medicine portfolios.

"From first-in-human studies to late-stage trials, the Clinical Sciences track offers hands-on experience across Regeneron's diverse pipeline—with opportunities to support innovative modalities and diverse indications—all guided by dedicated mentorship. The broad experiences in this program will help you discover your interests while equipping you with the skills to shape your career as a clinical scientist."

In Clinical Sciences, the Associate will:

- Participate in medical monitoring through the review of site clinical data and raising of medical queries
- Contribute to the development of clinical study designs and protocol writing
- Develop key documents such as expanded synopses, protocol amendments, investigator brochures, safety reports, and monitoring plans
- Design case report forms for studies and participate in user acceptance testing for databases
- Participate in and facilitate key meetings with sites such as those regarding dose escalation decisions
- Train internal team members and site on study protocol
- Become familiar with regulatory agency guidance for study design of relevant trial phases, therapeutic areas, and drug technology

FUNCTIONAL AREAS

TRACK 3
REGULATORY STRATEGY

In Regulatory Strategy, the Associate will support and provide project management for the operations governing pharmaceutical drug development to all aspects of Regeneron's quality, preclinical and clinical drug development programs, policies, and procedures meeting the necessary state of compliance relative to all regulatory commitments.

Current First Year PharmD Associate

DOUGLAS OBENRADER, PHARMD

Graduate of the University of Michigan

Currently working in Regulatory Program Management supporting the General Medicine portfolio.

"As a PharmD Associate at Regeneron, I have had the unique opportunity to immerse myself in the biopharmaceutical industry while deepening my understanding of regulatory strategy and related functions. The company's science-first mindset drives meaningful innovation, and through hands-on training and collaboration, I've been able to make a positive impact on multiple programs. The supportive community, continual mentorship, and dynamic projects have truly allowed me to grow both professionally and personally, all while advancing medicine for patients."

Current Second Year PharmD Associate

ALLISON NGUYEN, PHARMD

Graduate of Rutgers University

Currently working in Regulatory Strategy supporting the General Medicine portfolio.

"Regeneron is a company that is driven by people who are passionate about patient-centric innovation. The PharmD Program grants Associates with a unique opportunity to collaborate across a variety of functions and therapeutic areas. The program's focus on cutting-edge science and mentorship empowers Associates to develop valuable skills and make meaningful contributions to the development of life-saving medications."

In Regulatory Strategy, the Associate will:

- Participate in the development of regulatory strategies in collaboration with the development teams by conducting research and review of guidelines, regulatory precedence, and competitive intelligence
- Assist in managing the timelines, preparation, compilation, review, organization, and submission of regulatory deliverables including INDs, CTAs, BLAs, IND amendments, and BLA supplements in accordance with title 21 CFR and all FDA and ICH guidelines
- Support the drafting and review of regulatory documents, including briefing materials and labeling documents
- Manage overall completeness of scheduled submissions and coordinate with Regulatory Operations on submission timing and document status
- Participate in cross-functional departmental team projects and product development activities/meetings

FUNCTIONAL AREAS

TRACK 4
REGULATORY LABELING AND ADVERTISING & PROMOTION

In Regulatory Labeling and Advertising & Promotion, the Associate will gain knowledge on the role of Labeling throughout a drug's lifecycle, learn about the role of Ad Promo in the commercialization of drug products, and collaborate cross functionally with key stakeholders.

Current First Year PharmD Associate

TEMILOLUWA AWOLEYE, PHARMD

Graduate of Texas Southern University

Currently working in Regulatory Labeling Strategy supporting the Oncology portfolio.

"'Science to medicine' isn't just a saying here at Regeneron–it's our guiding principle and the litmus test for every discovery we pursue. Our mission is fueled by a deep dedication to the patients we are called to serve, and by a commitment to transforming groundbreaking scientific discoveries into life-changing medicines. For future candidates exploring the program, know that this is a place where innovation, collaboration, and purpose come together. Here, Associates are more than just a participant–we are valued members of the team, and our contributions truly matter."

Current Second Year PharmD Associate

RIYA VINOY, PHARMD

Graduate of St. John's University

Currently working in Regulatory Advertising & Promotion supporting the Immunology & Inflammation and Oncology portfolios.

"Regeneron is a company that relentlessly follows the science to bring innovative, life-changing medicines to patients. This program offers Associates the opportunity to engage with various functions in Global Development, with each track carefully curated to provide exposure to an array of invaluable experiences. Associates receive a unique blend of ownership over projects coupled with robust mentorship from senior leaders to facilitate meaningful contributions to our shared mission of revolutionizing patient care."

In Regulatory Labeling Strategy, the Associate will:

- Contribute to the development of healthcare provider (HCP) and patient labeling documents for regulatory submissions, including participating in Labeling Working Groups and obtaining management approval of labeling documents
- Manage the Labeling process throughout the product life cycle, prepare submission-ready labeling documents and support preparation of responses to Health Authorities during labeling negotiations
- Contribute to the development of labeling strategies through interpretation of regulations and guidelines

In Advertising & Promotion, the Associate will:

- Develop knowledge and skills to interpret FDA regulations and guidances to ensure promotional communication for HCPs and consumers is truthful and not misleading, and appropriately advise teams on associated regulatory risks
- Assist in FDA - Office of Prescription Drug Promotion (OPDP) interactions for assigned company products and maintain effective working relationship with FDA OPDP reviewers
- Monitor the external environment on evolving regulatory landscape related to product and disease state communications to strategically advise internal product and cross-functional teams

FUNCTIONAL AREAS

TRACK 5
SAFETY SCIENCES

In Safety Sciences, the Associate will gain a working knowledge of various disciplines that enable the continuous assessment of the benefit-risk of Regeneron products throughout their lifecycle, from early clinical development through market authorization and postmarketing surveillance, with a focus on signal detection and management. This includes gaining an understanding of safety data collection, evaluation, and reporting, establishing the framework for signal detection and management activities. There will be close collaboration with other disciplines within Global Development to provide a well-rounded perspective on how safety contributes to successful drug development and ensures safe use of Regeneron's products.

Current First Year PharmD Associate

ZOYA SOHAIL, PHARMD

Graduate of Rutgers University

Currently working in Safety Sciences supporting the General Medicine portfolio.

"The PharmD Program provides recent PharmD graduates with the opportunity to build upon their clinical education with specialized training in drug development across diverse functional areas. Associates acquire in-depth experience within their chosen track, and also are able to benefit from exposure to related functional areas and the interplay between them. Regeneron's science-driven and patient-centered culture creates an immersive and rewarding environment, empowering associates to launch fruitful careers in the biopharmaceutical industry."

Current Second Year PharmD Associate

ANDRE RICKARD, PHARMD

Graduate of Temple University

Currently working in Safety Sciences supporting Oncology portfolio.

"The PharmD Program has provided me with the opportunity to learn about the biopharmaceutical industry in great depth, while also being an integrated member of the team as I jump-start my career. The program supplies foundational training in safety sciences, while also allowing me to rotate through other related functions that I may not have been able to gain exposure to elsewhere. As a company, Regeneron truly does incredible work and I'm grateful to help in the advancement of medicine through the the PharmD Program."

In Safety Sciences, the Associate will:

- Understand Individual Case Safety Report (ICSR) data collection, evaluation, and reporting, including a working knowledge of safety database and tools
- Support preparation of safety aggregate reports for development and marketed products
- Understand business support functions for Global Patient Safety, including quality & compliance, standards & training, regulatory intelligence, and agreements & licensing
- Gain an understanding of how pharmacoepidemiology data plays a key role in the overall safety assessment through participation in the planning and execution of a pharmacoepidemiology project
- Participate and support signal detection activities, include data review, signal evaluation report preparation, drafting risk management plans, response to regulatory inquiries, and preparation of other safety submissions
- Organize, support, and participate in Safety Management Team (SMT) meetings

HOW HAS YOUR EXPERIENCE IN THE REGENERON PHARMD PROGRAM PREPARED YOU FOR YOUR ROLES?

"Regeneron is a company that provides exposure to the development of cutting-edge therapeutics, with innovative biotechnology and patients at the forefront. The PharmD Program presents an opportunity to explore multiple areas within Global Development, while also receiving support from senior leadership to encourage personal growth and development. The interdisciplinary nature of the program, as well as the emphasis placed on mentorship and learning, provides a unique introduction into the biopharmaceutical industry to prepare Associates for a successful career."

ALEXA BEHRENS, PHARMD
Manager, Clinical Study Lead
Former Development Operations & Portfolio Management PharmD Associate (2023-2025)



"The PharmD Program provided foundational training that allowed me to integrate seamlessly into development teams and contribute meaningfully to drug development. This training, paired with strong mentorship, was pivotal in preparing me for the role I'm in today."

HANNA SEO, PHARMD
Manager, Regulatory Affairs, Genetic Medicine - Neurology and Hematology
Former Regulatory Strategy PharmD Associate (2023-2025)

"The PharmD Program played a pivotal role in preparing me for my current role by offering unparalleled hands-on experiences and access to exceptional mentorship. This program equips its associates with a robust foundation in the biopharmaceutical industry, empowering them to make significant contributions to the development and sustainability of life-changing medications. The comprehensive training and diverse mentorship I received through this program have profoundly shaped my career growth and development as a professional in the industry."

NEHA PREM ANAND, PHARMD
Manager, Regulatory Labeling
Former Regulatory Labeling and Advertising & Promotion PharmD Associate (2023-2025)

"The PharmD Program has helped me build a strong foundation to succeed in my current role. The program provides its associates with rigorous training and amazing mentors, both of which were integral in growing my skills in Clinical Science as well as drug development as a whole."

JANAKI VEKARIA, PHARMD
Manager, Clinical Sciences
Former Clinical Sciences PharmD Associate (2022-2024)

APPLYING TO THE PHARMD PROGRAM

APPLY AT CAREERS.REGENERON.COM AND SEARCH THE PHARMD PROGRAM

- Application must **include CV and cover letter** submitted for track of interest
- Application deadline: **September 19th**
- Final interviews will be conducted **on-site**

IF YOU HAVE QUESTIONS, PLEASE CONTACT US AT

pharmdbp@regeneron.com

APPLICATION OPENS AT CAREERS.REGENERON.COM ON SEPTEMBER 2ND

ONLINE APPLICATION PORTAL CLOSES SEPTEMBER 19TH

INTERVIEWS WILL BE SCHEDULED WITH CANDIDATES DIRECTLY ONCE THE APPLICATION CLOSES

RECOMMENDATIONS ARE NOT REQUIRED TO BE SUBMITTED AS PART OF THE INITIAL APPLICATION. REFERENCES WILL BE COLLECTED AFTER FINAL OFFERS ARE EXTENDED

PROGRAM LEADERSHIP
EXECUTIVE PROGRAM SPONSORS

BARI KOWAL
Senior Vice President

Development Operations, Portfolio Management and Biostatistics
Data Management

MARY ALICE RAUDENBUSH
Vice President

CMC Regulatory Affairs

PROGRAM ADVISORS AND MENTORS

The program advisors are available to help navigate your experience, help you connect with resources within the company, and provide feedback to support your continued growth at Regeneron.

"I'm excited to be a program mentor where numerous opportunities exist for PharmD graduates to explore several departments. Our 'science first' culture at Regeneron, which fosters curiosity, collaboration, and exploration, is embedded into the program, giving us opportunities to continually learn and grow at the company."

MIRIAM KORE, PHARMD
Executive Director, Therapeutic Area Operations Leader

"The PharmD Program is a two-way avenue, where PharmD graduates have a unique opportunity to learn and contribute to the cutting-edge science and drug development that is performed across several departments, and at the same time it allows Regeneron Associates to advance their people managing and mentoring skills."

OLIVIER HARARI, MD
Vice President, Genetic Medicines Clinical Development

"As a former PharmD post-doctoral program graduate, I am delighted to be involved in the direct mentorship of innovative pharmaceutical leaders entering the workforce. We will work to seamlessly integrate our Associates into exciting programs to enable their continued growth, independence and competency as they strive to help the company reach program goals."

DONATO FORLENZA, PHARMD
Senior Director, Regulatory Affairs

PROGRAM ADVISORS AND MENTORS

"It is truly energizing to work at Regeneron where you are surrounded by exceptionally talented individuals in a highly collaborative environment, all working together to progress great science and improve patient lives. Our PharmD Associates have a unique opportunity to not only learn through observing and shadowing, but also to actually manage projects on their own within a short time frame and feel the impact of their contributions, as they learn. It is extremely rewarding to be a part of such a program."

PEARL RAWSON, PHARMD
Executive Director, Regulatory Labeling and Advertising & Promotion

"The PharmD Program provides the opportunity for PharmD graduates to get the best-in-class training at one of the most scientifically-minded biotech organizations. Regeneron is deeply rooted in its belief of "doing well by doing good", reflected in every aspect of our work. There's wide recognition that our people are our most important asset, and developing talent from within enables our mission of advancement in science and ultimately benefiting patients. I am very proud to be part of this important program!"

STEPHANIE BIEDERMANN
Senior Director, Development Program Management

"The PharmD Program provides a unique opportunity for PharmDs to gain valuable industry experience as integral team members in a global matrixed environment. The program offers foundational, hands-on experience working on meaningful assignments independently and cross-functionally, with access to resources, tools, and technology. Regeneron's program connects the PharmD's clinical education with broader applications in the pharmaceutical industry setting, positioning pharmacists to understand their impact on regulatory, safety, and operational aspects. I am proud to represent Global Patient Safety as a board member for this rewarding program and support the next generation of aspiring industry leaders."

NICOLE PERNA, PHARMD
Director, Global Patient Safety

"I'm very excited to be a board member and a mentor for this program to share my passion for drug development and mentoring highly engaged and committed individuals like yourself to achieve your goals to be the next generation of leaders. This program will offer you an opportunity to explore and find your passion for the area of your interest and to continually learn and grow in The Regeneron Way where we Lead With Science, Take On Big Ideas, Make It Happen, Be Great Together, and Do What's Right. At Regeneron, it's all about the PATIENT!"

YAMINI PATEL, PHD
Vice President, Global Program Head

Q&A

1

WHAT IS THE DIFFERENCE BETWEEN A FELLOWSHIP AND OUR PHARMD PROGRAM?

Our program has **no university affiliation,** allowing for complete attention towards your professional development and engagement in the Regeneron community. Associates of the program are **full-time employees** of Regeneron and are given the opportunity to be fully contributing members of the team. Members of the program experience full company benefits while being able to thrive in an active learning environment.

2

DO YOU CHOOSE YOUR THERAPEUTIC AREA OR IS IT ASSIGNED TO YOU?

Designation of therapeutic area is decided based on a combination of personal interests, business need, and availability of team members to mentor new Associates.

3

WHEN WILL WE HEAR BACK AFTER WE SUBMIT OUR APPLICATION?

Applicants should submit their materials by September 19th for consideration. Applicants will be contacted after the submission deadline regarding interviews.

4

TO WHOM SHOULD THE COVER LETTER AND OTHER APPLICATION REQUIREMENTS BE ADDRESSED?

Please address your letter of intent to:
Applicant Reviewers
The PharmD Program | Regeneron Pharmaceuticals
777 Old Saw Mill River Rd, Tarrytown, NY 10591

CLINICAL PRODUCT CANDIDATES

Phase 1	Phase 2	Phase 3	Approved
vonsetamig (BCMAxCD3) **REGN5837** (CD22xCD28) **REGN7945** (CD38xCD28) **REGN9533** (Factor XII) **ALN-F1202**‡ (Factor XII)	**REGN9933** (Factor XI) **REGN7508** (Factor XI) **REGN7999** (TMPRSS6)	**pozelimab + cemdisiran**‡ (anti-C5 + C5 siRNA) **odronextamab** (CD20xCD3) **linvoseltamab** (BCMAxCD3) **nexiguran ziclumeran**# (TTR)	Arcalyst® (rilonacept) † EYLEA® (aflibercept) Injection ° ZALTRAP® (ziv-aflibercept) § EYLEA HD® (aflibercept) Injection ° DUPIXENT® (dupilumab) * Praluent® (alirocumab) Injection LIBTAYO® (cemiplimab-rwlc) KEVZARA® (sarilumab) *
REGN4336 (PSMAxCD3) **27T51** (MUC16 CAR-T) **REGN10597** (PD-1-IL2Ra-IL2)	**ubamatamab** (MUC16xCD3) **REGN5668** (MUC16xCD28) **nezastomig** (PSMAxCD28) **REGN7075** (EGFRxCD28) **davutamig** (METxMET)	**cemiplimab** (PD-1) **fianlimab** (LAG-3)	
ALN-PNP‡ (PNPLA3) **ALN-ANG3**‡ (ANGPTL3) **ALN-SOD**‡ (SOD1) **ALN-HTT02**‡ (HTT) **ALN-APOC3**‡ (APOC3) **REGN13335** (PDGFβ) **REGV131-LNP1265**# (Factor 9) **ALN-CIDEB**‡ (CIDEB)	**REGN5381/REGN9035** (NPR1) **rapirosiran**‡ (HSD17B13) **trevogrumab** (GDF8) **DB-OTO** (AAV Gene Therapy)Δ **REGN7544** (NPR1 antagonist)	**garetosmab** (Activin A) **mibavademab** (LEPR)	
	sarilumab* (IL-6R)	**dupilumab*** (IL-4R) **itepekimab*** (IL-33) **REGN5713-5715** (Bet v 1) **REGN1908-1909** (Fel d 1)	Evkeeza® (evinacumab-dgnb) ** Inmazeb® (atoltivimab, maftivimab, and odesivimab - ebgn) Injection Veopoz® (pozelimab-bbfg) Injection LYNOZYFIC® (linvoseltamab-gcpt)
		aflibercept 8 mg° (VEGF)	

Approx. 45 product candidates

HEMATOLOGY | SOLID ORGAN ONCOLOGY | INTERNAL/GENETIC MEDICINES | I&I | OPHTHALMOLOGY

Agreement with: *Sanofi; ‡Alnylam; #Intellia;
*Bayer, **Ultragenyx
†Kiniksa is solely responsible for development and commercialization of ARCALYST
§Sanofi is solely responsible for development and commercialization of ZALTRAP
ΔDiscovered by Decibel Therapeutics

As of August 2025.

This slide contains investigational drug candidates that have not been approved by any regulatory authority.

REGENERON BY THE NUMBERS

OUR SCIENCE & MEDICINES

14
medicines approved in the U.S. and/or other countries

~45
product candidates in clinical development across multiple therapeutic areas

~50
countries with clinical trials

~2.9M
exomes sequenced to date by the Regeneron Genetics Center®

OUR COMPANY

15.1K+
Regeneron employees worldwide

Top 5
ranking as a *Science* Top Employer for fourteen consecutive years

$5.1B
R&D investment in 2024

35+
Years of scientific leadership

OUR RESPONSIBILITY

Top 10%
ranking in biotech industry across 3 leading ESG ratings

3.2M+
students reached by Regeneron STEM initiatives since 2020

52%
employee volunteerism rate in 2024

6
consecutive years on the Dow Jones Sustainability Index (DJSI)

TECHNOLOGY AND MARKETED PRODUCTS

Our core capabilities for target discovery and validation are enabled by a series of Regeneron-invented technologies that accelerate, improve and disrupt the traditional drug discovery and development process. Collectively, these technologies represent some of the most valuable biotechnologies ever created, and aid our efforts to continuously accelerate the average timeline from discovery to drug approval — ultimately allowing us to help more patients around the world, faster. We will continue to raise the bar for R&D excellence and productivity in the biotech industry.

FDA-APPROVED & MARKETED MEDICINES*

EYLEA HD (aflibercept) Injection 8 mg [4]

KEVZARA (sarilumab) [3]
Please see full Prescribing Information including Boxed WARNING for KEVZARA.

DUPIXENT (dupilumab) Injection [2]

EYLEA (aflibercept) Injection [4]

Inmazeb (atoltivimab, maftivimab, and odesivimab – ebgn) Injection
16.67 mg / 16.67 mg / 16.67 mg per mL

Arcalyst (rilonacept) [1]

LIBTAYO (cemiplimab-rwlc)

Veopoz (pozelimab-bbfg) Injection
Please see full Prescribing Information including Boxed WARNING for Veopoz.

Evkeeza (evinacumab-dgnb) [6]

Praluent (alirocumab) Injection [5]

ZALTRAP (ziv-aflibercept) [3]

LYNOZYFIC (linvoseltamab-gcpt)

1. Commercialized by Kiniksa Pharmaceuticals, Ltd.
2. Commercialized with Sanofi
3. Commercialized by Sanofi
4. Commercialized by Regeneron in the United States and Bayer outside the United States
5. Commercialized by Regeneron in the United States and Sanofi outside the United States
6. Commercialized by Regeneron in the United States and Ultragenyx Pharmaceuticals Inc. outside the United States

Regeneron has become one of the great science-driven companies of our generation, with numerous approved treatments, a nearly entirely homegrown pipeline and the best technologies in the business. We got here by following the science and trusting our people. But at Regeneron, we're never done. Our goal is to continue pushing the boundaries of science, to the extent that we aren't even able to imagine the breakthroughs and cures we will be known for in ten or twenty years. It's an incredible time to be at Regeneron, as we stand on the edge of an unprecedented future.

GEORGE D. YANCOPOULOS, MD, PHD
Co-Founder, Board Co-Chair, President and Chief Scientific Officer

AWARDS AND RECOGNITIONS

TIME: **World's Most Sustainable Companies**, 2025

Disability:IN & American Association of People with Disabilities: **Best Place to Work for Disability Inclusion**, 2025

Biospace: **Best Place to Work**, 2025

LexisNexis: **Innovation Momentum – The Global Top 100**, 2025

Forbes: **America's Best Employers for Women**, 2025

Newsweek: **America's Greenest Companies**, 2025

Civic 50: **Most Community-Minded Companies in the Nation**, 2025

Human Rights Foundation: Corporate Equality Index, 2025

Science: **Top Employer**, 2024

Dow Jones Sustainability World & North America INdex, 2024

US News & World Report: **Best Companies to Work for**, 2024

Newsweek: **America's Most Responsible Companies,** 2024

Newsweek: **America's Greatest Workplaces for Diversity**, 2024

Fast Company: **Best Workplaces for Innovators**, 2023

ABOUT OUR LOCATION

The PharmD Program is located primarily in Tarrytown, NY. Tarrytown is located along the eastern bank of the Hudson River, about 25 miles north of midtown Manhattan.

For over 35 years, the Westchester County community has helped us grow. Because of that, we've been actively expanding our existing 1.7 million square feet of state-of-the-art laboratory resources that employ more than 4,000 passionate employees across the region who all have the same mission—advancing the delivery of life-saving medicines for the growing number of patients in need.



Put the world at your doorstep. With our region's reliable interconnected roadways, bus stations, rail lines and leading regional airport, traveling around the world is as convenient as traveling around our county.

Feel safe and secure. Our highly ranked, safe neighborhoods are home to some of the nation's leading healthcare systems, so you can ensure you have the resources you need —around the block.

Set up success. Westchester's strong school districts, top graduation rates and several colleges and universities provide opportunity for the success of you and your family.

Enjoy your weekdays and your weekends. Westchester has an abundance of restaurants, performing-arts venues, sports centers, special events, and night life that make it easy to fill your weekend but difficult to choose how.


REGENERON
SCIENCE TO MEDICINE®
CREATE THE FUTURE YOU BELIEVE IN
IF YOU HAVE QUESTIONS, PLEASE CONTACT US AT
pharmdbp@regeneron.com